Search

Displaying results 2301 - 2310 of 10000 in total
  1. Drug

    Zidovudine

    go.drugbank.com/drugs/DB00495
    ApprovedInvestigational

    A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. … This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains.

    Mixtures: LAMIVUDINA E ZIDOVUDINA MYLAN, LAMIVUDINA E ZIDOVUDINA MYLANCategories: Antivirals used in combination for the treatment of HIV infections
  2. Drug

    Oteseconazole

    go.drugbank.com/drugs/DB13055
    ApprovedInvestigational

    [A247035] This is possible thanks to the tetrazole moiety in oteseconazole that increases target selectivity. … [A247050] The use of oteseconazole is contraindicated in females of reproductive potential due to its embryo-fetal toxicity risks.[L41635] This drug was approved by the FDA on April 26, 2022.

  3. Drug

    Clorazepic acid

    go.drugbank.com/drugs/DB00628
    ApprovedIllicit

    Similar to other benzodiazepines, the active metabolite of clorazepate enhances the binding of gamma-aminobutyric acid (GABA) to the GABA type A (GABA-A) receptor, which promotes channel opening and neuronal … Also, the use of clorazepate exposes users to users to the risks of abuse, misuse, and addiction, and its continued use may lead to significant physical dependence.

    Products: Tranxene T-Tab, Clorazepate Dipotassium T-Tab
  4. Drug

    DaxibotulinumtoxinA

    go.drugbank.com/drugs/DB17929
    ApprovedInvestigational

    [L47865] On August 14, 2023, the drug was also approved for the treatment of cervical dystonia. … [A261075, L47860] DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines.

  5. Drug

    Asparaginase Escherichia coli

    go.drugbank.com/drugs/DB00023
    ApprovedInvestigational

    For patients who develop hypersensitivity to _E. coli_-derived formulations of L-asparaginase, the use of PEGylated or non-PEGylated [DB08886] is recommended [A31999]. … Asparaginase from _E. coli_ has clinically shown to exhibit antitumor actions in models of leukaemias [A31996, A31997].

    Synonyms: Asparaginase (E. coli), E. coli Asparaginase
  6. Drug

    Difamilast

    go.drugbank.com/drugs/DB14987
    ApprovedInvestigational

    [L55042, A275424, A275420] As difamilast's mechanism of action involves the inhibition of PDE4, the inhibition leads to an increase in intracellular cyclic AMP and a subsequent decrease in the production … The drug is indicated for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 2 years of age and older [L55042]. It is approved in Japan and the United States.

  7. Drug

    Fostamatinib

    go.drugbank.com/drugs/DB12010
    ApprovedInvestigational

    It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, L52150]. Fostamatinib has also been granted orphan drug status by the FDA [L2644]. … Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK

  8. Drug

    Fomivirsen

    go.drugbank.com/drugs/DB06759
    ApprovedWithdrawn

    The drug was withdrawn by the FDA because while there was a high unmet need for drugs to treat CMV when the drug was initially discovered and developed due to the CMV arising in people with AIDS, the development … Fomivirsen is marketed under the trade name Vitravene for intravitreal injection and was the first antisense drug to be approved by the Food and Drug Administration (FDA).

  9. Drug

    Venlafaxine

    go.drugbank.com/drugs/DB00285
    ApprovedInvestigational

    [L43030] The immediate formulation of the drug, marketed as Effexor, was first approved by the FDA in 1993 and the extended-release formulation, Effexor XR, was later introduced in 1997. … for the management of neuropathic pain (although there is only minimal evidence of efficacy for this condition).

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: VENLAVITAE® 75 MG CÁPSULAS DURAS DE LIBERACIÓN PROLONGADA
  10. Drug

    Hexocyclium

    go.drugbank.com/drugs/DB06787
    Approved

    Hexocyclium is a muscarinic acetylcholine receptor antagonist which was presumably used in the treatment of gastric ulcer or diarrhea. … Proton pump inhibitors like [DB00338] and opiate anti-diarrheal agents like [DB00836] have largely replaced the use of anti-muscarinics in the treatment of gastric ulcers and diarrhea due to their more